What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?

被引：4
作者：
Verma, S [1 ]
Trudeau, M
Dranitsaris, G
Clemons, M
Joy, AA
MacKey, JR
机构：
[1] Sunnybrook & Womens Hlth Sci Ctr, Toronto, ON, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 25期
关键词：
D O I：
10.1200/JCO.2004.00.9886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6260 / 6260
页数：1
相关论文
共 5 条
[1]   Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].
Blum, JL ;
Jones, SE ;
Buzdar, AU ;
LoRusso, PM ;
Kuter, I ;
Vogel, C ;
Osterwalder, B ;
Burger, HU ;
Brown, CS ;
Griffin, T .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493
[2]   Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer [J].
Keller, AM ;
Mennel, R ;
Georgoulias, VA ;
Nabholtz, JM ;
Erazo, A ;
Lluch, A ;
Vogel, CL ;
Kaufmann, M ;
von Minckwitz, G ;
Henderson, IC ;
Mellars, L ;
Alland, L ;
Tendler, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) :3893-3901
[3]   Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer [J].
O'Shaughnessy, JA ;
Blum, J ;
Moiseyenko, V ;
Jones, SE ;
Miles, D ;
Bell, D ;
Rosso, R ;
Mauriac, L ;
Osterwalder, B ;
Burger, HU ;
Laws, S .
ANNALS OF ONCOLOGY, 2001, 12 (09) :1247-1254
[4]   Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines [J].
Talbot, DC ;
Moiseyenko, V ;
Van Belle, S ;
O'Reilly, SM ;
Conejo, EA ;
Ackland, S ;
Eisenberg, P ;
Melnychuk, D ;
Pienkowski, T ;
Burger, HU ;
Laws, S ;
Osterwalder, B .
BRITISH JOURNAL OF CANCER, 2002, 86 (09) :1367-1372
[5]  
Verma S, 2004, BREAST CANCER RES TR, V88, pS201
1